Application
KCTD13 Antibody (C-term) western blot analysis in HepG2 cell line lysates (35ug/lane).This demonstrates the KCTD13 antibody detected the KCTD13 protein (arrow).| Product Name | KCTD13 Antibody (C-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | KCTD13; BACURD1; PDIP1; POLDIP1; BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 1; BTB/POZ domain-containing protein KCTD13; Polymerase delta-interacting protein 1; TNFAIP1-like protein |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WB |
| WB:1:100~500 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | BACURD1 PDIP1 POLDIP1 |
|---|---|
| Alternative Names | KCTD13 BACURD1 PDIP1 POLDIP1 BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 1 BTB/POZ domain-containing protein KCTD13 Polymerase delta-interacting protein 1 TNFAIP1-like protein |
| Molecular Weight(MW) | 36357 Da |
| Function | Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex involved in regulation of cytoskeleton structure. The BCR(BACURD1) E3 ubiquitin ligase complex mediates the ubiquitination of RHOA, leading to its degradation by the proteasome, thereby regulating the actin cytoskeleton and cell migration |
| Tissue Specificity | Expressed in a wide variety of tissues. |
| Cellular Localization | Nucleus. |
| Entrez Gene | 253980 |
|---|---|
| Nucleotide Accession | NP_849194.1 |
Application
KCTD13 Antibody (C-term) western blot analysis in HepG2 cell line lysates (35ug/lane).This demonstrates the KCTD13 antibody detected the KCTD13 protein (arrow).| Application Notes | WB:1:100~500 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
